Frontida BioPharm, Inc. is a US-based CDMO focused on developing and manufacturing immediate / controlled release oral delivery products. We offer unique technology platforms for controlled release Oral Solid Dosages and fixed-dose combinations. Technologies include: AdaptDose™ encapsulation of mini-tablets / granules for customized strengths / delivery rates; Duragran® controlled release / ODT beadlet technology; solvent processing for granulations / coatings; DEA Schedule II – V product development/manufacture; and High Potent Active (HPAI) formulations, with 3BB tablets/capsules annual capacity. Our R&D team has proven success in developing complex dosage forms. At Frontida (the Greek word meaning “caring”), we put the utmost care into everything we do. Our teams in Philadelphia & Aurora, IL are experienced in developing / manufacturing products for cardiovascular, GI, endocrine, CNS conditions and infectious diseases. We strive to ensure our partners’ business goals are achieved.